Gemfibrozil

• Description:

  Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

• Product Name Alternative:

  CI-719

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Cytochrome P450; PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Metabolic Disease; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Gemfibrozil.html

• Concentration:

  10mM

• Purity:

  99.91

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (O) C (C) (C) CCCOC1=CC (C) =CC=C1C

• Molecular Formula:

  C15H22O3

• Molecular Weight:

  250.34

• Precautions:

  H302

• References & Citations:

  [1]Pahan K, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277 (48) :45984-91. Epub 2002 Sep 18.|[2]Almad A, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011 Dec;232 (2) :309-17.|[3]Wang JS, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30 (12) :1352-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  CYP1; CYP2; PPARα

• CAS Number:

  25812-30-0